| Name | Title | Contact Details |
|---|
The massage franchise started in 2004 and has grown to more than 120 Retreats throughout North America by providing personalized wellness treatment options through therapeutic massage and skincare services. Massage Heights is a family-owned massage and wellness franchise dedicated to elevating the lives of others by providing Members and Guests with professional, affordable and resort-quality massage, skincare and wellness services.
Marcus Institute is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Development Centers Inc is a Detroit, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
F45 Training is a dynamic and ever-evolving leader in innovation across the health and fitness industry. Always pioneering, F45’s training methods set the benchmark in fitness and functional training, delivering results for clients every day. T...
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.